AUTOINFLAMMATORY DISEASES IN HEMATOLOGY FROM DIAGNOSIS TO TREATMENT

AUTOINFLAMMATORY_DISEASES_IN_HEMATOLOGY_FROM_DIAGNOSIS_TO_TREATMENTkapak

CLASSIFICATION OF INFLAMMATORY HEMATOLOGICAL DISEASES (IHD)

Sinan Mersin

İstanbul Demiroğlu Science University, Faculty of Medicine, Florence Nightingale Hospital Department of Hematology, İstanbul, Türkiye

Mersin S. Classification of Inflammatory Hematological Diseases (IHD). In: Kurt Yüksel M, editor. Autoinflammatory Diseases in Hematology from Diagnosis to Treatment. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.25-35.

ABSTRACT

Inflammatory hematological diseases (IHDs) represent a complex group of disorders characterized by immune dysregulation affecting hematologic function. This chapter provides a structured overview of IHDs, focusing on current classification systems and challenges in standardization. Beginning with the definition and pathogenesis of IHDs, it traces the evolution of classification nomenclature, highlighting historical cases and the progression toward integrated genetic, immunologic, and phenotypic criteria. Key limitations, such as the overlap with autoimmune and autoinflammatory conditions, are examined, illustrating the need for more precise diagnostic boundaries. Commonly accepted frameworks, including genetic markers, immune pathway disruptions, and clinical phenotypes, are reviewed to outline current classification methods. Addressing the pressing issues in achieving universal classification, this chapter explores emerging concepts in precision medicine, biomarker discovery, and AI-driven diagnostics. By reflecting on both historical insights and future innovations, it aims to guide hematologists in navigating the complexities of IHD classification, ultimately facilitating improved patient outcomes.

Keywords: Inflammation; Hematological diseases; Classification

Referanslar

  1. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383(23):2255-2273. [Crossref]  [PubMed]  [PMC]
  2. Hayden A, Park S, Giustini D, Lee AY, Chen LY. Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review. Blood Rev 2016;30(6):411-420. [Crossref]  [PubMed]
  3. Patel AR, Desai PV, Banskota SU, Edigin E, Manadan AM. Hemophagocytic Lymphohistiocytosis Hospitalizations in Adults and Its Association With Rheumatologic Diseases: Data From Nationwide Inpatient Sample. J Clin Rheumatol. 2022;28(1):e171-e174. [Crossref]  [PubMed]
  4. Sykes DB, Schroyens W, O'Connell C. The TEMPI syn drome--a novel multisystem disease. N Engl J Med. 2011;365(5):475-477. [Crossref]  [PubMed]
  5. Bidier M, Zschoche C, Gholam P, Enk AH, Hadaschik EN. Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes. Acta Derm Venereol 2012;92(4):408-409. [Crossref]  [PubMed]
  6. Ilyas AA, Quarles RH, Dalakas MC, Brady RO. Polyneuropathy with monoclonal gammopathy: glycolipids are frequently antigens for IgM paraproteins. Proc Natl Acad Sci USA. 1985;82(19):6697-6700. [Crossref]  [PubMed]  [PMC]
  7. Offit K, Macris NT, Finkbeiner JA. Monoclonal hypergammaglobulinemia without malignant transformation in angioimmunoblastic lymphadenopathy with dysproteinemia. Am J Med. 1986;80(2):292-294. [Crossref]  [PubMed]
  8. Patel N, Dulau-Florea A, Calvo KR. Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome. Semin Hematol. 2021;58(4):204-211. [Crossref]  [PubMed]
  9. Chen LYC, Quach TTT. COVID-19 cytokine storm syndrome: a threshold concept. Lancet Microbe. 2021; 2(2):e49-e50. [Crossref]  [PubMed]
  10. Reeh H, Rudolph N, Billing U, Christen H, Streif S, Bullinger E, et al. Response to IL-6 transand IL-6 classic signalling is determined by the ratio of the IL-6 receptor  to gp130 expression: fusing experimental insights and dynamic modelling. Cell Commun Signal. 2019;17(1):46. [Crossref]  [PubMed]  [PMC]
  11. Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine. 2014;70(1):11-20. [Crossref]  [PubMed]
  12. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627-2632. [Crossref]  [PubMed]
  13. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013;13(6):397-411. [Crossref]  [PubMed]  [PMC]
  14. Hrycek A, Cieślik P, Szkróbka W, Pajak J. Kikuchi-Fujimoto disease: a case report. Rheumatol Int 2005;26(2):179-181. [Crossref]  [PubMed]
  15. Honda F, Tsuboi H, Toko H, Ohyama A, Takahashi H, Abe S, et al. Recurrent Kikuchi-Fujimoto Disease Successfully Treated by the Concomitant Use of Hydroxychloroquine and Corticosteroids. Intern Med. 2017;56(24):3373-3377. [Crossref]  [PubMed]  [PMC]
  16. Abla O, Jacobsen E, Picarsic J, Krenova Z, Jaffe R, Emile JF, et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018;131(26):2877-2890. [Crossref]  [PubMed]  [PMC]
  17. Rae W, Ward D, Mattocks CJ, Gao Y, Pengelly RJ, Patel SV, et al. Autoimmunity/inflammation in a monogenic primary immunodeficiency cohort. Clin Transl Immunology. 2017;6(9):e155. [Crossref]  [PubMed]  [PMC]
  18. Soy M, Atagündüz P, Atagündüz I, Sucak GT. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic. Rheumatol Int 2021;41(1):7-18. [Crossref]  [PubMed]  [PMC]
  19. Matson DR, Yang DT. Autoimmune Lymphoproliferative Syndrome: An Overview. Arch Pathol Lab Med. 2020;144(2):245-251. [Crossref]  [PubMed]  [PMC]
  20. Cunha BA, Durie N, Selbs E, Pherez F. Fever of unknown origin (FUO) due to Rosai-Dorfman disease with mediastinal adenopathy mimicking lymphoma: diagnostic importance of elevated serum ferritin levels and polyclonal gammopathy. Heart Lung. 2009;38(1):83-88. [Crossref]  [PubMed]
  21. Stubbins RJ, Cherniawsky H, Chen LYC, Nevill TJ. Innovations in genomics for undiagnosed diseases: vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. Cmaj 2022;194(14):E524-e527. [Crossref]  [PubMed]  [PMC]
  22. Arranz L, Arriero MDM, Villatoro A. Interleukin-1 as emerging therapeutic target in hematological malignancies and potentially in their complications. Blood Rev. 2017; 31(5):306-317. [Crossref]  [PubMed]
  23. Ogilvie AC, Hack CE, Wagstaff J, van Mierlo GJ, Erenberg AJ, Thomsen LL, et al. IL-1 beta does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/ nitrate release when used in patients with cancer. J Immunol. 1996;156(1):389-394. [Crossref]  [PubMed]
  24. Slaats J, Ten Oever J, van de Veerdonk FL, Netea MG. IL1/IL-6/CRP and IL-18/ferritin: Distinct Inflammatory Programs in Infections. PLoS Pathog 2016;12(12):e1005973. [Crossref]  [PubMed]  [PMC]
  25. Tani C, Elefante E, Arnaud L, Barreira SC, Bulina I, Cavagna L, et al. Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation. Clin Exp Rheumatol 2022;40 Suppl 134(5):93-102. [Crossref]  [PubMed]
  26. Leng SX, Margolick JB. Aging, sex, inflammation, frailty, and CMV and HIV infections. Cell Immunol 2020;348:104024. [Crossref]  [PubMed]  [PMC]